Ankilozan spondilitli hastalarda güncel tedavi yaklaşımları

Öz

Ankilozan spondilit (AS) başlıca sakroiliak eklemler ve omurgayı etkileyen kronik, inflamatuar bir romatizmal hastalık olarak, daha çok erkeklerde sıklıkla 2. ve 3. On yılda ortaya çıkan bir hastalıktır. AS’li hastalarda tedavinin temelini ağrı ve inflamasyonu azaltan nonsteroid anti-inflamatuar ilaçlar (NSAİİ) almaktadır. Modifiye edici antiromatizmal (DMARD) ilaçlar, AS hastalığın tedavisinde etkinliği kanıtlanamamıştır. DMARD’ların kullanımı semptomların iyileştirilmesinde yeterli bulunmamıştır. Son zamanlarda anti tümör nekrozis faktör (TNF) blokerleri olan Golimumab, Etanersept, Adalimumab, İnfliksimab gibi ajanlar AS tedavisinde umut verici sonuçlar vermektedir. TNF blokerleri AS hastalarının fiziksel işlevlerinde, yaşam kalitesinde ve semptomlarında iyileşme sağlamaktadır. Bu yazı AS’li hastaların güncel farmakolojik tedavisi üzerine odaklanmıştır. Anahtar kelimeler: Ankilozan spondilit, tedavi, tümör nekrozis faktör alfa inhibitörü, hastalık modifiye edici ilaç- lar

Anahtar Kelimeler

• Ankilozan spondilit, tedavi, tümör nekrozis faktör alfa inhibitörü, hastalık modifiye edici ilaçlar

Current treatment approaches in patients with ankylosing spondylitis

Öz

Ankylosing spondylitis (AS) is a chronic, inflammatory, rheumatic disease that mainly affects sacroiliac joints and spine. AS predominantly occurs more often in males and typically begins in the second or third decade. The mainstay of therapy in AS are nonsteroidal anti-inflammatory drugs, which reduce inflammation and pain. Disease modifying antirheumatic drugs (DMARD) did not have enough evidence to prove their effect in AS treatment. The use of DMARD may not sufficient to improve the treatment and symptoms. Currently, TNF-blockers such as, Golimumab Etanersept Adalimumab İnfliksimab have promising results in the treatment of AS. TNF-blockers improve the clinical signs and symptoms, and improve the patients’ physical function and quality of life. This manuscript is focused that Current pharmacological treatments in patients with ankylosing spondylitis

Anahtar Kelimeler

• Ankylosing spondylitis, treatment, tumour necrosis factor alpha inhibitor, disease modifying antirheumatic drugs

Kaynakça

1. van der Linden S, van der Heijde D. Ankylosing spondylitis.
2. Clinical features. Rheum Dis Clin North Am 1998;24:663-
3. , vii.
4. Weisman MH RJ, Heijde D. Ankilozan Spondilit ve Spondiloartropatiler.
5. Ankara: Veri Medikal Yayıncılık; 2008.
6. Dougados M, Dijkmans B, Khan M, et al. Conventional treatments
7. for ankylosing spondylitis. Annals of the rheumatic diseases
8. , 61 Suppl 3:iii 40-50.

9. Lavie F, Pavy S, Dernis E, et al. Pharmacotherapy (excluding
10. biotherapies) for ankylosing spondylitis: development of recommendations
11. for clinical practice based on published evidence
12. and expert opinion. Joint Bone Spine 2007;74:346-352.
13. Kwan D, William R. Bartle, and Scott E. Walker. The effects of
14. acetaminophen on pharmacokinetics and pharmacodynamics
15. of warfarin. J Clin Pharmacol 1999;9: 68-75.
16. Şahin E. Farmakolojik ajanlar. Fiziksel Tıp ve Rehabilitasyon
17. Pratik El Kitabı. Tan CJ, editör. Şendur ÖF, Çeviri ed. 2.baskı
18. İstanbul: Güneş Tıp Kitabevleri;2008. p.333-357.
19. Melli M, Kayaalp SO. Non-Steroidal antiinflamatuar ilaçlar.
20. Kayaalp SO (Editör). Rasyonel Tedavi Yönünden Tibbi Farmakoloji
21. Baskı. Ankara: Hacettepe-Taş;2005 p.837-870.
22. Maugars Y, Mathis C, Berthelot JM, et al: Assessment of
23. the efficacy of sacroiliac corticosteroid injections in spondylarthropathies:
24. a double-blind study. Brit J Rheumatol
25. ;35:767-770.
26. van den Berg R, Baraliakos X, Braun J, van der Heijde D. First
27. update of the current evidence for the management of ankylosing
28. spondylitis with non-pharmacological treatment and nonbiologic
29. drugs: a systematic literature review for the ASAS/
30. EULAR management recommendations in ankylosing spondylitis.
31. Rheumatology 2012;51:1388-1396.
32. Braun J, Pham T, Sieper J, et al: International ASAS consensus
33. statement for the use of anti-tumour necrosis factor agents
34. in patients with ankylosing spondylitis. Ann Rheum Dis
35. ;62:817-824.
36. Ozgocmen S, Akgul O, Altay Z, et al: Expert opinion and key
37. recommendations for the physical therapy and rehabilitation
38. of patients with ankylosing spondylitis. Int J Rheum Dis
39. ;15:229-238.
40. Brooks P. Slow acting anti rheumatic drugs and cytotoxic
41. agents. In: Schumacher HR, ed. Primer on the Rheumatic Diseases.
42. Atlanta: Arthritis Foundation; 1993. p303-6
43. Zochling J, van der Heijde D, Dougados M, Braun J: Current
44. evidence for the management of ankylosing spondylitis: a systematic
45. literature review for the ASAS/EULAR management
46. recommendations in ankylosing spondylitis. Ann Rheum Dis
47. ;65:423-432.
48. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major
49. clinical response (BASDAI 50) to tumour necrosis factor
50. α blockers in ankylosing spondylitis. Ann Rheum Dis,
51. ;63:665-670.
52. Braun J. V, Van Den Berg R, Baraliakos X, et al. 2010 update
53. of the ASAS/EULAR recommendations for the management
54. of ankylosing spondylitis. Ann Rheum dis 2011;70: 896-904.
55. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010
56. Update of the international ASAS recommendations for the
57. use of anti-TNF agents in patients with axial spondyloarthritis.
58. Annals of the rheumatic diseases 2011;70:905-908.
59. van der Heijde D, Dijkmans B, Geusens P, et al. Ankylosing
60. Spondylitis Study for the Evaluation of Recombinant Infliximab
61. Therapy Study G: Efficacy and safety of infliximab in
62. patients with ankylosing spondylitis: results of a randomized,
63. placebo-controlled trial (ASSERT). Arthrit Rheum
64. ;52:582-591.
65. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing
66. spondylitis with infliximab: a randomised controlled multicentre
67. trial. The Lancet 2002;359:1187-1193.
68. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant
69. human tumor necrosis factor receptor (etanercept) for treating
70. ankylosing spondylitis: a randomized, controlled trial. Arthrit
71. Rheum 2003; 48:3230-3236.
72. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety
73. of golimumab in patients with ankylosing spondylitis: results
74. of a randomized, double-blind, placebo-controlled, phase III
75. trial. Arthrit Rheum 2008; 58:3402-3412.
76. Braun J, Davis J, Dougados M, et al. First update of the international
77. ASAS consensus statement for the use of anti-TNF
78. agents in patients with ankylosing spondylitis. Ann Rheum
79. Dis 2006; 65:316-320.
80. Saag KG, Teng GG, Patkar NM, et al. American College of
81. Rheumatology 2008 recommendations for the use of nonbiologic
82. and biologic disease-modifying antirheumatic drugs in
83. rheumatoid arthritis. Arthrit Care Res 2008;59:762-784.
84. Black R A, Rauch CT, Kozlosky CJ, et al. A metalloproteinase
85. disintegrin that releases tumour necrosis factor-R from cells.
86. Nature 1997;385:729-733.
87. Pay S. Romatizmal Hastalıklarda Anti-TNF İlaç Kullanımı.
88. Turkiye Klinikleri J Med Sci, 2006;26:430-440.
89. Gorman JD, Sack, K E, Davis JC Jr. Treatment of ankylosing
90. spondylitis by inhibition of tumor necrosis factor α. N Engl J
91. Med 2002;346:1349-1356.
92. Dvis JC, Webb A, Lund S, Sack K, Result from an open-label
93. extension study of etanercept in ankylosing spondylitis. Art
94. Rheum 2004;51:302-104
95. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and
96. safety of etanercept after readministration in patients with active
97. ankylosing spondylitis. Rheum 2005;44:342-348.
98. Den Broeder AA, Saxne T, Heinegård D, et al. Long term antitumour
99. necrosis factor α monotherapy in rheumatoid arthritis:
100. effect on radiological course and prognostic value of markers
101. of cartilage turnover and endothelial activation. Ann Rheum
102. Dis 2002; 61:311-318.
103. U.S Food and Drug administration, Full prescribing information,
104. Adaliumab.2008. Available at:www.fda.gov.
105. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor
106. antagonist mechanisms of action: a comprehensive review.
107. Pharmacol Ther 2008;117:244-279.
108. Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers
109. in patients with ankylosing spondylitis and non-radiographic
110. axial spondyloarthritis: a meta-analysis. Ann Rheum Dis
111. doi:10.1136/ 2014-205322 [Epub ahead of print]
112. Patel Aarat M, and Larry W. Moreland. “Certolizumab pegol:
113. a new biologic targeting rheumatoid arthritis. Ann Rheum Dis
114. ;6: 855-866.
115. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action
116. of certolizumab pegol (CDP870): In vitro comparison with
117. other anti-tumor necrosis factor α agents. Inflamm Bowel Dis
118. ;13:1323-1332.
119. Evans Ashley T, Lee SD. “A review and expert opinion of the
120. use of certolizumab for Crohn’s disease. Expert Opin Biol
121. Ther 2012; 12:363-370.
122. Landewé R, Braun, J, Deodhar A, et al . Efficacy of certolizumab
123. pegol on signs and symptoms of axial spondyloarthritis
124. including ankylosing spondylitis: 24-week results of a double-blind
125. randomised placebo-controlled Phase 3 study. Ann
126. Rheum Dis 2013;73:39-47.
127. Dhillon S: Certolizumab pegol: a review of its use in patients
128. with axial spondyloarthritis or psoriatic arthritis. Drugs
129. ;74:999-1016.
130. Braun J, Davis J, Dougados M, et al. First update of the international
131. ASAS consensus statement for the use of anti-TNF
132. agents in patients with ankylosing spondylitis. Ann Rheum
133. Dis 2006;65:316-320.
134. Davis JC. Ankylosing Spondylitis In: Koopman WJ, Moreland
135. LW (eds). Arthritis and Allied Conditions. A Textbook
136. of Rheumatology Lippincott Williams and Wilkins P. 2005
137. p.1319-1333.
138. Braun Jv, Van Den Berg R, Baraliakos X, et al. : 2010 update
139. of the ASAS/EULAR recommendations for the management
140. of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.